Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
|Articles|June 14, 2022
Daily Medication Pearl: Raloxifene Hydrochloride (Evista)
Author(s)Saro Arakelians, PharmD
Raloxifene hydrochloride (Evista) is indicated for the treatment and prevention of osteoporosis in postmenopausal women, as well as to lower the risk of invasive breast cancer in postmenopausal women with osteoporosis.
Advertisement
Medication Pearl of the Day: Evista (raloxifene hydrochloride)
Indication: Raloxifene hydrochloride (Evista) is an estrogen agonist/antagonist indicated for the treatment and prevention of osteoporosis in postmenopausal women, as well as to lower the risk of invasive breast cancer in postmenopausal women with osteoporosis.
Insight:
- Dosing: 60 mg tablet orally once daily.
- Dosage forms: Tablets (not scored) 60 mg.
- Adverse events:Adverse reactions (>2% and more common than with placebo) include hot flashes, leg cramps, peripheral edema, flu syndrome, arthralgia, and sweating.
- Mechanism of action: Raloxifene is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator. The biological actions of raloxifene are largely mediated through binding to estrogen receptors.
Source:
Advertisement
Related to this article
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Authors of a pharmacist-directed transitions-of-care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
A single infusion reversed new-onset type 1 diabetes (T1D) in more than half of treated mice by strengthening regulatory T cells and driving autoreactive CD8+ T cells into a less destructive state.
In a Pharmacy Times interview, study coauthor William J. Peppard, PharmD, discusses the association between suzetrigine and fewer opioid refills after knee replacement, the limits of the evidence, and the access barriers pharmacists can help patients navigate.
The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.
Novo's topline phase 3 data show 12.4% weight loss with CagriSema 1.0 mg/1.0 mg in type 2 diabetes and 21.0% in adults with overweight or obesity.
Marissa Reigelman of US Pharmacopeia explains how single-country dependence on key starting materials, combined with low prices, has kept 5 critical injectable drugs in shortage for more than a decade.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
2
CagriSema Tops Tirzepatide 5 mg for Weight Loss in REIMAGINE 5
3
Engineered Stem Cell Therapy Reverses New-Onset T1D in Mice by Reprogramming T Cells
4
Ramantamig's 93.6% ORR and Outpatient CRS Control
5